Spexis AG
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase … Read more
Spexis AG (SPEX) - Total Liabilities
Latest total liabilities as of December 2023: CHF14.49 Million CHF
Based on the latest financial reports, Spexis AG (SPEX) has total liabilities worth CHF14.49 Million CHF as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Spexis AG - Total Liabilities Trend (2019–2023)
This chart illustrates how Spexis AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Spexis AG Competitors by Total Liabilities
The table below lists competitors of Spexis AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shankar Lal Rampal Dye-Chem Limited
NSE:SRD
|
India | ₹206.18 Million |
|
NICO Resources Limited
OTCGREY:NICOF
|
USA | $712.50K |
|
Trilogiq
PA:ALTRI
|
France | €3.75 Million |
|
Cruz Cobalt Corp
PINK:BKTPF
|
USA | $376.63K |
|
Taiga Motors Corporation
PINK:TAIMF
|
USA | $93.19 Million |
|
PT Solusi Bangun Indonesia Tbk
F:RU6
|
Germany | €7.94 Trillion |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
India | ₹1.26 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Spexis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spexis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spexis AG (2019–2023)
The table below shows the annual total liabilities of Spexis AG from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | CHF14.49 Million | +37.35% |
| 2022-12-31 | CHF10.55 Million | -46.38% |
| 2021-12-31 | CHF19.67 Million | -40.88% |
| 2020-12-31 | CHF33.28 Million | -11.64% |
| 2019-12-31 | CHF37.66 Million | -- |